Keyphrases
AIDS/HIV
66%
Confidence Interval
56%
HIV Patients
52%
CD4 Count
48%
EuroSIDA
48%
Europe
47%
Human Immunodeficiency Virus Type 1 (HIV-1)
47%
Combined Antiretroviral Therapy (cART)
33%
HIV-positive
31%
Antiretroviral Therapy
31%
Red Blood Cells
25%
Antibody-dependent Cellular Cytotoxicity
25%
Highly Active Antiretroviral Therapy (HAART)
24%
Israel
23%
Viral Load
22%
Lymphocytes
20%
Donor-acceptor
19%
Cytotoxicity
19%
D Study
17%
AIDS-defining Illness
17%
Lysis
17%
Non-AIDS Comorbidities
17%
HIV Infection
16%
Non-AIDS Events
14%
Antiphospholipid Syndrome
14%
Hepatitis C Virus
14%
Incidence Rate
13%
Infected Individual
13%
Virological Failure
13%
Mortality Rate
13%
Human Red Blood Cells
13%
Cell Count
13%
Liver-related Mortality
12%
Human Lymphocytes
12%
Erythrocytes
12%
Chronic Kidney Disease
12%
Abacavir
12%
Infected Patients
12%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
11%
Malignancy
11%
Relative Rate
11%
Platelets
11%
Hazard Ratio
10%
Myocardial Infarction
10%
Antiviral Drugs
10%
Relative Risk
10%
Phagocytosis
10%
Immune Response
10%
Hepatitis C
10%
Clinical Outcomes
9%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
CD4 Lymphocyte Count
42%
Cytotoxicity
36%
Human Immunodeficiency Virus 1
29%
Viral Load
27%
Lymphocyte
23%
Antibody-Dependent Cell-Mediated Cytotoxicity
17%
Phagocytosis
17%
Human Immunodeficiency Virus Infection
15%
CD4
14%
Blood Plasma
14%
Erythrocyte
12%
Target Cell
12%
Platelet
11%
T Cell
11%
Viremia
10%
Glomerulus Filtration
9%
Macrophage Inflammatory Protein 1
8%
Monoclonal Antibody
8%
CD14
8%
Cell Count
8%
Multiple Sclerosis
8%
Rho(D) Immune Globulin
8%
Mononuclear Phagocyte
8%
Pneumocystis Carinii
7%
Antiserum
7%
Peptides
6%
Cell Population
6%
Humoral Immunity
6%
Peripheral Blood Mononuclear Cell
6%
Epitope
6%
Acquired Immune Deficiency Syndrome
6%
Autoantibodies
6%
RNA Virus
5%
Myelin
5%
Lymphocyte Subpopulation
5%
Leukocyte
5%
Innate Lymphoid Cell
5%
Antiphospholipid Syndrome
5%
CD8
5%
Prevalence
5%
Adoptive Immunity
5%
Hemoglobin Blood Level
5%
Intravenous Immunoglobulin
5%
Transplantation Antigen
5%
Effector Cell
5%
Lupus Anticoagulant
5%
Thrombocyte Antibody
5%
Lupus Erythematosus
5%
Medicine and Dentistry
Human Immunodeficiency Virus
94%
Antiretroviral Therapy
24%
Diseases
19%
Cell Count
18%
Acquired Immune Deficiency Syndrome
17%
Cancer
14%
Hazard Ratio
13%
Immune Deficiency
11%
Lymphocyte
10%
Highly Active Antiretroviral Therapy
9%
Hepatitis C Virus
9%
Prospective Cohort Study
9%
Infection
9%
Cellular Immunity
8%
Hypersensitivity
8%
Cytotoxicity
8%
Restylane
8%
Nevirapine
8%
Chronic Kidney Disease
8%
Bisexuality
8%
Lung
8%
Lung Lavage
6%
Proteinase Inhibitor
6%
Respiratory Distress
6%
Colon
6%
Thorax Radiography
6%
Glomerular Filtration Rate
6%
In Vitro
5%
Drug Use
5%
Diabetes Mellitus
5%
Target Cell
5%
Antiphospholipid Syndrome
5%
Nonnucleoside Reverse Transcriptase Inhibitor
5%
Efavirenz
5%
Cohort Analysis
5%
Pneumocystis Pneumonia
5%
Atazanavir
5%
Hepatitis Virus
5%
Mast Cell Degranulation
5%
Viremia
5%
Methyldopa
5%
